Status:
COMPLETED
Pruritus and Melanoma and Cutaneous Carcinomas Treated With Immunotherapy
Lead Sponsor:
University Hospital, Brest
Conditions:
Pruritus
Eligibility:
All Genders
18+ years
Brief Summary
Immune checkpoint inhibitors (ICIs) are commonly used in the therapeutic arsenal of metastatic melanoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma, thanks to their inhibiting effects...
Eligibility Criteria
Inclusion
- age 18 years and older,
- treated with ICIs (nivolumab, pembrolizumab, ipilimumab, cemiplimab) for melanoma, squamous cell carcinoma or Merkel cell carcinoma
- not having formulated any opposition
Exclusion
- age under 18 years,
- adults not legally competent,
- presence of pruritus at the inclusion,
- participation refusal
Key Trial Info
Start Date :
August 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 22 2019
Estimated Enrollment :
181 Patients enrolled
Trial Details
Trial ID
NCT04365244
Start Date
August 19 2019
End Date
November 22 2019
Last Update
April 28 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609
2
CH de Landerneau
Landerneau, France